deltatrials
Completed PHASE3 NCT00931632

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth

Sponsor: Mallinckrodt

Conditions Bronchopulmonary Dysplasia
Interventions Inhaled Nitric Oxide Placebo
Updated 8 times since 2017 Last updated: Oct 30, 2017 Started: Nov 30, 2009 Primary completion: May 31, 2013 Completion: May 31, 2014

This PHASE3 trial investigates Bronchopulmonary Dysplasia and is currently completed. Mallinckrodt leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Nov 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Feb 2017 — Nov 2017 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mallinckrodt
Data source: Mallinckrodt

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augusta, United States, Calgary, Canada, Fort Worth, United States, Greenville, United States, Hartford, United States, Indianapolis, United States, Livingston, United States, Loma Linda, United States, Louisville, United States, Milwaukee, United States and 21 more location s